

Drug Utilization Review Board

(DUR Board)

Meeting – January 13, 2010 @ 6:00 p.m.

Oklahoma Health Care Authority

4545 N. Lincoln Suite 124

Oklahoma City, Oklahoma 73105

Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. December 9, 2009 DUR Minutes – Vote
 - B. December 10, 2009 DUR Recommendation Memorandum
 - C. Correspondence

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Medication Coverage Activity Audit for December 2009
 - B. Help Desk Activity Audit for December 2009

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 5. 30 Day Notice to Prior Authorize Antipsychotics – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Chonlahan, Dr. Muchmore, Chairman:

- 6. 30 Day Notice to Prior Authorize Ribavirin Capsules, Solution, and Dose Packs – See Appendix D.**
 - A. Product Summary
 - B. Cost Comparison
 - C. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of NSAIDs and 30 Day Notice to Prior Authorize Zipsor™ and Cambia™ – See Appendix E.**
 - A. Current PA Criteria
 - B. Utilization Review
 - C. Market News & Updates
 - D. COP Recommendations
 - E. Utilization Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Topical Antifungals – See Appendix F.**
 - A. Current PA Criteria
 - B. Utilization Review
 - C. Market News & Updates
 - D. COP Recommendations
 - E. Utilization Details

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

9. **FDA and DEA Updates – See Appendix G.**
10. **Future Business**
 - A. Anxiolytic Criteria Review
 - B. Annual Review of Smoking Cessation Products
 - C. Annual Review of HFA Products
 - D. New Product Reviews
11. **Adjournment**